Wednesday, September 26, 2018 2:00 PM – 3:00 PM Improving Quality of Life for Patients with Tumors: 82. Implication of biomarker mutations for predicting survival in patients with metastatic lung disease to the spine

Abstract

BACKGROUND CONTEXT Spinal metastases are a major cause of morbidity in patients with cancer. Molecular profiling strategies to characterize lung cancer have identified several genetic biomarkers that may lead to more effective prognostication. PURPOSE The aim of this study was to ascertain whether gene expression signatures in patients with advanced metastatic disease are associated with survival, when the disease has progressed to the spine. PATIENT SAMPLE We identified every consecutive patient at our institution with metastatic lung cancer who underwent surgery for spinal metastases from 2011 to 2017. Inclusion criteria were the availability of genetic mutational data through chart review, and the existence of any known metastatic lesion in the body and spine at the time of presentation. OUTCOME MEASURES Median overall survival (OS) was recorded following both diagnosis and surgical treatment. METHODS Genetic mutations in ALK, MET, ROS1, EGFR, and KRAS were chosen a priori for study based on availability by standard SNaPshot Lung Tumor Genotyping Analysis. Survival time was the duration between treatment for spinal metastases and death. Kaplan-Meier methods and the log-rank test were applied to characterize survival data. RESULTS Twenty-six patients met criteria for inclusion. Median survival following surgery was 0.67 years. Median overall survival (OS) following diagnosis was 2.7 years. The presence of molecular abnormalities in patients with spinal metastases was significantly associated with increased OS(HR 0.38, 95% CI 0.12-1.22, P=.03). CONCLUSIONS Molecular phenotyping may provide prognostic insight in patients undergoing surgery for spinal metastases. This is the first study to demonstrate an association between genetic mutational data and OS in this patient population. It also represents the largest published series of such patients (n=26) for which genetic mutational data are reported. Future models estimating survival for patients with spinal metastases may be enhanced by incorporation of molecular criteria. FDA DEVICE/DRUG STATUS This abstract does not discuss or include any applicable devices or drugs.